PMID- 28553179
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1450-1147 (Print)
IS  - 1607-3312 (Electronic)
IS  - 1450-1147 (Linking)
VI  - 16
IP  - 2
DP  - 2017 Apr-Jun
TI  - Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE for Metastatic 
      Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia 
      Type 1 and Cushing's Syndrome.
PG  - 126-132
LID - 10.4103/1450-1147.203068 [doi]
AB  - Neuroendocrine tumor (NET) occurring in association with other endocrine 
      syndromes forms a distinct entity. The aim was to assess the therapy response 
      profile of the routine peptide receptor radionuclide therapy (PRRT) in this 
      relatively uncommon but clinically challenging subgroup of patients. A 
      retrospective analysis was undertaken from the case records from those who were 
      treated with (177)Lu-DOTATATE for metastatic NET. In addition to assessing the 
      therapeutic efficacy, emphasis was also given to study lesional sites and scan 
      pattern. A total of 5 cases were found: In this series of five cases, four 
      belonged to multiple endocrine neoplasia type 1 (MEN1) syndrome; in these four 
      MEN1 syndrome patients, the primary site of NET was thymic region (n = 1), 
      duodenum (n = 1), and pancreas (n = 2). The fifth case was of Cushing's syndrome 
      with the primary site of NET in the thymus. A good symptomatic response was 
      observed in all MEN1 syndrome cases (100%) and progression of symptoms in the 
      patient with Cushing's syndrome. The biochemical response (assessed by 
      measurement of tumor marker serum chromogranin A) demonstrated very good partial 
      response (defined by more than 75% reduction of tumor marker) in 2 MEN1 cases and 
      Cushing's syndrome, good partial response (25-75% reduction of tumor marker) in 
      the remaining 2 MEN1 cases. Scan wise (assessed by technetium 
      [(99m)Tc]-hydrazinonicotinamide [HYNIC]-tektrotyd [TOC]/(68)Ga-DOTA-NOC/TATE 
      positron emission tomography-computed tomography [PET-CT] and fluorodeoxyglucose 
      [FDG] PET-CT) partial response was observed in 3 MEN1 cases, stable disease was 
      noted in one MEN1 case and disease progression was noted in the patient with 
      Cushing's syndrome. The change in FDG uptake was found to be an important 
      sensitive scan parameter in the treatment evaluation of NETs compared to 
      somatostatin receptor-based imaging in the cases with low MiB1 index. In our 
      series, good palliative response to (177)Lu-DOTA-octreotate (DOTATATE) PRRT was 
      observed in most NET patients associated with MEN1 syndrome without any major 
      hematological or renal toxicity.
FAU - Naik, Chinna
AU  - Naik C
AD  - Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre 
      Annexe, Parel, Mumbai, Maharashtra, India.
FAU - Basu, Sandip
AU  - Basu S
AD  - Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre 
      Annexe, Parel, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - World J Nucl Med
JT  - World journal of nuclear medicine
JID - 101286955
PMC - PMC5436318
OTO - NOTNLM
OT  - 177Lu-DOTATATE
OT  - multiple endocrine neoplasia
OT  - neuroendocrine tumor
OT  - peptide receptor radionuclide therapy
COIS- There are no conflicts of interest.
EDAT- 2017/05/30 06:00
MHDA- 2017/05/30 06:01
PMCR- 2017/04/01
CRDT- 2017/05/30 06:00
PHST- 2017/05/30 06:00 [entrez]
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2017/05/30 06:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - WJNM-16-126 [pii]
AID - 10.4103/1450-1147.203068 [doi]
PST - ppublish
SO  - World J Nucl Med. 2017 Apr-Jun;16(2):126-132. doi: 10.4103/1450-1147.203068.